Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diva LaboratoriesROCO:4153 -1.88%74 Operating Margin % is 14.70% as of Dec. 2025, which is 61% above its 10-year median of 9.11. GuruFocus rates ROCO:4153 with a GF Score™ of 74/100 and a GF Value™ of NT$38.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Diva Laboratories ranks better than 74.38% on this metric.
Diva Laboratories Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Diva Laboratories's Operating Margin % or its related term are showing as below:
ROCO:4153'
s Operating Margin % Range Over the Past 10 Years
Min: -5.06 Med: 9.11 Max: 12.59
Current: 12.59
ROCO:4153's Operating Margin % is ranked better than 74.38% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.35
vs ROCO:4153: 12.59
Diva Laboratories's 5-Year Average Operating Margin % Growth Rate was 16.90% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Diva Laboratories Operating Margin % Related Terms
Diva Laboratories Operating Margin % Historical Data
* Premium members only.
The historical data trend for Diva Laboratories's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4153 vs TMO, DHR, IDXX: Operating Margin % Comparison
For the Diagnostics & Research subindustry, Diva Laboratories's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diva Laboratories Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Diva Laboratories's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Diva Laboratories's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diva Laboratories (ROCO:4153) has a Operating Margin % of 14.70% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Diva Laboratories and its competitors. This is 61% above median its historical median of 9.11. According to the industry distribution chart, Diva Laboratories ranks #52 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 25.6%.
Is Diva Laboratories' Operating Margin % too high?
Diva Laboratories' current Operating Margin % of 14.70% is 61% above median its 10-year median of 9.11. Based on the distribution chart, Diva Laboratories ranks #52 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diva Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diva Laboratories' Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diva Laboratories ranks #52 out of 203 companies for Operating Margin %. This puts Diva Laboratories in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Diva Laboratories and its competitors. Diva Laboratories's current Operating Margin % is 14.70%, which is 61% above median its own 10-year median of 9.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diva Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Diva Laboratories (ROCO:4153) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.03, compared to a current price of NT$31.25 — trading 17.8% below its estimated fair value. The current Operating Margin % is 14.70%, which is 61% above median its 10-year median of 9.11. Diva Laboratories' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Diva Laboratories (ROCO:4153), the current Operating Margin % is 14.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diva Laboratories (ROCO:4153) Overvalued in 2026?
Based on GuruFocus' analysis, Diva Laboratories stock appears to be undervalued.
The current stock price of NT$31.25 is trading 17.8% below its estimated GF Value™ of NT$38.03.
GuruFocus considers Diva Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4153:
Operating Margin %: 14.70% (61% above median its 10-year median of 9.11)
GF Value™: NT$38.03 vs. price of NT$31.25 (17.8% below fair value)
No single metric tells the full story. See the ROCO:4153 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diva Laboratories Ltd is engaged in the sale, manufacturing and development of medical equipment and computer-related devices. Its products are divided into Medical display which includes radiology, endo/surgical, touch, and embedded display; and Industrial display which includes touch display monitors. It derives revenue from sale of Medical monitors, Medical parts, Industrial monitors, Industrial parts, and Parts. Geographically it operates and derives revenue from Taiwan.
74GF Score
Get the complete analysis for ROCO:4153
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4153 has been successfully added to your 
